Astra, Daiichi granted EU nod for Enhertu in first-line breast cancer

RegulatoryapprovedEnhertuPositive

AI Analysis

Summary

AstraZeneca and Daiichi Sankyo received European Union approval for Enhertu (trastuzumab deruxtecan) in first-line breast cancer treatment, marking a significant regulatory milestone for the drug.

Outcome Details

EU approval for Enhertu in first-line breast cancer

Importance:8/10

Sentiment:

0.80

regulatory approvalEU approvaloncologybreast cancerEnhertu

Related Companies

$AZN $DSKYF

Read the original article

Published by Seeking Alpha Healthcare on September 1, 2026 4:15 PM

Read Original